Article: Experimental drug blocks prostate cancer progression in animal study

Report from Asian News International brought to you by HT Syndication.

Washington, May 23 -- Researchers at Ohio State University Comprehensive Cancer Center have developed an experimental agent that has been able to block the progression of prostate cancer in an animal study.

The agent, OSU-HDAC42, blocked the progression of prostate cancer in an animal model with an aggressive form of the disease.

OSU-HDAC42 belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds developed to reactivate genes that normally protect against cancer but are turned off by the cancer process.

The study showed that the agent kept mice with a precancerous condition from ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!